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Short Communications and Brief Case Notes
Hypersensitivity to acetylsalicylic acid (ASA) and 
other nonsteroidal anti-infl ammatory drugs (NSAIDs) is a 
relatively common condition in patients with chronic urticaria 
and in adults with asthma [1], with a self-reported prevalence 
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of less than 2% in the general population [2]. Increased 
production of cysteinyl leukotrienes due to the interference 
of NSAIDs with cyclooxygenase (COX) metabolism is a 
possible physiopathological pathway underlying the clinical 
manifestations [3]. In recent years, COX-2 selective inhibitors 
have been proposed as valid alternatives for patients with 
hypersensitivity to ASA or NSAIDs [4]. However, in a small 
percentage of very sensitive patients who may also react to 
paracetamol, which is a very weak COX inhibitor, even these 
new drugs are not tolerated and this problem is a challenge 
in clinical practice [5,6]. 
The authors report the clinical data from a period of 5 
years for 2 asthmatic patients with sensitivity to multiple 
NSAIDs (including COX-2 selective inhibitors and 
paracetamol). We present the outcome of administration 
of montelukast, a leukotriene receptor antagonist, which 
was also indicated for the control of their mild respiratory 
atopic disease. 
Both patients were females, aged 30 and 41 years. They 
were referred for a 10-year history of severe generalized 
urticaria and angioedema occurring less than 1 hour after 
the intake of 500 mg of ASA or paracetamol. At the time 
of referral, due to the progressive severity of the reactions, 
they did not have any suitable medication to control fever 
or pain. Both patients had also had persistent rhinitis and 
mild persistent asthma since childhood. Symptoms were 
under control with low doses of inhaled steroids. They had 
normal lung function and were both atopic, both sensitized 
to mite and 1 to grass and Parietaria judaica.
Over a period of approximately 1 month, we performed 
single-blind placebo controlled challenges with the more 
selective COX-2 inhibitors available in our market at 
that time (meloxicam, 7.5 mg, and nimesulide, 100 mg) 
and also with paracetamol (500 mg); responses were 
positive (generalized urticaria and angioedema) and were 
controlled with symptomatic treatment. Subsequently they 
were started on montelukast 10 mg per day as a single 
treatment, to treat their mild asthma and rhinitis. After 4 
and 6 weeks of treatment, respectively, we performed new 
single-blind placebo controlled challenges with meloxicam 
(7.5 mg) and paracetamol (1000 mg), obtaining negative 
results. Both patients continued montelukast as their single 
asthma-control therapy, rarely needing to use short-acting 
bronchodilators for relief. They were also able to take the 
allowed anti-infl ammatory and antipyretic drugs on an as-
needed basis with full tolerance.
In both these patients with ASA/NSAID and paracetamol 
sensitivity, the use of montelukast allowed the as-needed 
intake of these drugs over a period of 5 years. We have tried 
the same approach in 3 nonatopic patients with intolerance 
to paracetamol and NSAIDs, but none of them achieved 
tolerance to these drugs while using montelukast 10 mg daily 
for 2 weeks before challenges (data available on request).
Consistent with our results, Pérez et al [7] demonstrated 
that leukotriene antagonists can inhibit skin reactions at least 
partially in 60% of patients with reactions related to NSAID 
use. This has also been shown by other authors [8]. Also in 
line with our data, more recently Serrano et al [9] reported 
the effi cacy of montelukast in preventing adverse reactions 
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to NSAIDs, COX-2 selective inhibitors, and paracetamol 
in a 52-year-old patient. Nevertheless, montelukast could 
not prevent severe allergic reaction to diclofenac in another 
case [10].
In conclusion, we report the usefulness of montelukast 
in providing clinically signifi cant tolerance to paracetamol 
and meloxicam used on an as-needed basis by atopic asthma 
patients with hypersensitivity to these drugs. Although not 
observed in placebo-controlled conditions, these fi ndings 
were confi rmed over a follow-up of 5 years. However, 
based on our experience this approach does not seem to 
be effective in nonatopic patients, using a 10-mg dose 
of montelukast. In patients with NSAID hypersensitivity 
who have a clinical indication to take these drugs on a 
regular basis, a tolerance induction protocol could be an 
alternative.
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Ticks frequently cause human disease by transmitting 
infectious agents (protozoa, rickettsia, bacteria, and 
viruses) [1]. Toxic local reactions are common, but systemic 
immunoglobulin (Ig) E-mediated reactions after tick bites are 
very seldom reported. Allergy to Argas refl exus [2], Ixodes 
ricinus [3], Ixodes holocyclus [4] and Ixodes pacifi cus [5] 
is well documented, but there is only 1 case of allergy to 
Rhipicephalus species in the literature [6]. We now report a 
case of anaphylaxis due to Rhipicephalus sanguineous.
A 58-year-old goatherd was referred to our service for 
evaluation after he experienced heavy sweating, sickness, 
chest tightness, dyspnea, and loss of consciousness after a 
tick bite. On arrival at the hospital during that episode, his 
systolic blood pressure was 80 mm Hg and oxygen saturation 
was 88%. He was vomiting and had generalized urticaria. Two 
ticks were found on his skin. He responded to epinephrine, 
antihistamines and corticosteroids. Afterwards, he reported to 
us that he had had a similar reaction after a tick bite 5 years 
ago and that he had a history of severe, recurrent reactions 
after tick bites. He had no history of previous allergies or 
family allergies. 
Proteins from the whole body of ticks were extracted with 
phosphate buffered saline by stirring for 1 hour at 4ºC. The 
soluble fraction was separated by centrifugation at 22 000g 
for 20 minutes at 4ºC. The tick extract was then dialyzed 
against distilled water, fi ltered, and lyophilized. The protein 
concentration of the extract (24% wt/wt) was determined 
(Biorad, Hercules, California, USA).
Specifi c IgE against tick extract was measured by an 
enzyme allergosorbent test according to the manufacturer’s 
instructions (Hytec-Specifi c IgE EIA, Hycor Biomedical Inc, 
Garden Grove, California, USA).
Protein extract of tick was separated by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Separated protein bands were electrophoretically transferred 
to polyvinylene difluoride membranes. The binding of 
IgE antibody to allergens was analyzed by Western blot 
using serum from the allergic patient and antihuman 
immunoglobulin (Ig) E peroxidase conjugate (Dako, 
Carpinteria, California, USA). Chemiluminescence detection 
reagents (Western Lightning Chemiluminescence Reagent 
Plus, Perkin Elmer, Boston, Massachusetts, USA) was added 
following the manufacturer’s instructions.
The skin prick test did not indicate sensitization to 
common inhalants, foods, Anisakis simplex, latex, amoxicillin, 
